Sigmedical Services S.R.L.
- Address
- lock Available on a paid plan
Sigmedical Services S.R.L. - Advanced Oncology Research Center
Sigmedical Services S.R.L. is a leading clinical research center specializing in advanced oncology trials, with particular expertise in immunotherapy and targeted therapy investigations. The center has established itself as a key contributor to phase III and phase II studies evaluating novel therapeutic combinations and biosimilars across multiple cancer types, demonstrating extensive experience in complex oncology trial management.
- Non-Small Cell Lung Cancer (NSCLC) research, including KRAS G12C mutations, EGFR Exon 20 insertions, and immunotherapy combinations
- HER2-positive cancers including breast cancer and gastric/gastroesophageal junction cancers with monoclonal antibody therapies
- Gastrointestinal malignancies, encompassing esophageal squamous cell carcinoma and gastroenteropancreatic neuroendocrine tumors
- Novel immunotherapy combinations using checkpoint inhibitors (pembrolizumab, nivolumab, dostarlimab) with emerging agents
The center maintains a robust portfolio of cutting-edge trials investigating antibody-drug conjugates, biosimilar equivalence studies, and innovative combination therapies. With proven capabilities in managing multinational studies requiring blinded independent central review (BICR) and comprehensive biomarker assessments including PD-L1 expression profiling, Sigmedical Services demonstrates commitment to advancing precision oncology through participation in pivotal registration trials across both solid tumors and rare cancer subtypes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 57 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 56 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Merck Sharp & Dohme LLC3active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC5trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sigmedical Services S.R.L.
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 57 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 11 | Unknown | 2018-08-24 | 2025-06-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.